Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 8/20 | 0.52 |
| ▸ | CASP3 | P42574 | 4/20 | 0.52 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | IL1B | P01584 | 1/20 | 0.36 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10252183 | 1.00 | CASP1 (0.52) | CASP1CASP3CASP8MMEACE | |
| SCHEMBL10200737 | 1.00 | CASP1 (0.52) | CASP1CASP3CASP8MMEACE | |
| SCHEMBL644997 | 0.93 | CASP1 (0.60) | CASP1CASP3CASP8MMEACE | |
| SCHEMBL1409707 | 0.93 | CASP1 (0.60) | CASP1CASP3CASP8MMEACE | |
| SCHEMBL1414605 | 0.93 | CASP1 (0.60) | CASP1CASP3CASP8MMEACE | |
| SCHEMBL10285149 | 0.92 | CASP1 (0.53) | CASP1CASP3CASP8MMEACE | |
| SCHEMBL12522494 | 0.92 | CASP1 (0.53) | CASP1CASP3CASP8MMEACE | |
| SCHEMBL10262665 | 0.92 | CASP1 (0.53) | CASP1CASP3CASP8MMEACE | |
| SCHEMBL4356685 | 0.89 | CASP1 (0.49) | CASP1CASP3CASP8MMEACE | |
| SCHEMBL647366 | 0.89 | CASP1 (0.49) | CASP1CASP3CASP8MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238749-A1 | INHIBITORS OF INTERLEUKIN-1 BETA CONVERTING ENZYME | IL1B, IL1A, IL1R1 | CASP1 5/4885CASP3 542/4885CASP8 309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.